Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01877 JUNSHI BIO
RTNominal up9.870 +0.060 (+0.612%)
Others

22/10/2021 15:58

Junshi Bio (01877) gets acceptance notice from NMPA

[ET Net News Agency, 22 October 2021] Shanghai Junshi Biosciences Co., Ltd. (01877)
said Suzhou Kebo Ruijun Biosciences Co., Ltd., a company jointly invested by the company
and Beijing Eirene Biotech Co., Ltd., has received the Acceptance Notice issued by the
National Medical Products Administration. The investigational new drug application for the
JS019 injection (project code: JS019) has been accepted.
The active ingredient of JS019 injection is a recombinant humanised anti-CD39 monoclonal
antibody. CD39 is the enzyme responsible for the initial steps in the conversion of immune
stimulatory extracellular adenosine triphosphate (ATP) to immune suppressive adenosine
(ADO) in the tumour microenvironment, and plays an important role in the immune
suppressive response in the tumour microenvironment. (RC)

Remark: Real time quote last updated: 28/03/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.